Nintedanib (Ofev) is accepted for use within NHS Scotland for treatment of chronic fibrosing interstitial lung diseases

Treatment is approved in adults for the treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype other than idiopathic pulmonary fibrosis and is supported by the NHS Scotland Patient Access Scheme.

Scottish Medicines Consortium